E-Learning Center
Join Our Network
OncoFacts

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

XXXConference NameXXX


Register Now

Great Debates and Updates in Hematologic Malignancies

April 30 - May 1, 2010

New York, New York, USA

Westin New York Times Square

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been approved for 12.5 of AMA PRA Category 1 CreditTM.

 

Who Should Attend
This educational activity is primarily targeted to academic and community hematologists and oncologists, and secondarily to oncology nurses and other health care professionals interested in the management of patients with hematologic malignancies.

 

Objectives
After successful completion of this course, attendees should be able to:

  • Identify the most effective therapeuticstrategies and novel combinations for acute leukemias, especially for the care of
    elderly patients
  • Correctly utilize imaging techniques to ensure successful management and validate response criteria for patients with
    non-Hodgkin’s lymphoma
  • Review traditional treatment strategies for lymphoma and decide whether emerging, updated therapies could potentially
    optimize patient outcomes
  • Determine how the emergence of novel agents in multiple myeloma could affect the use of markers for patient risk
    stratification and approaches to overcome treatment resistance
  • Evaluate the optimal frontline approach to multiple myeloma treatment, including the most favorable number of agents,
    treatment sequencing, inclusion of novel agents, and the use of bisphosphonates for symptom management
  • Determine how to effectively manage multiple myeloma patients with preexisting complications

 

Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, New York

Morton Coleman, MD, FACP
Center for Lymphoma and Myeloma
Weill Medical College of Cornell
University
The New York-Presbyterian Hospitals
New York, New York

Jorge E. Cortes, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Harold P. Erba, MD, PhD
University of Michigan Medical Center
Ann Arbor, Michigan

Eric J. Feldman, MD
Weill-Cornell Medical College
New York, New York

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Guillermao Garcia-Manero, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Hagop M. Kantarjian, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota

John P. Leonard, MD
Weill Cornell Medical College
New York, New York

Sagar Lonial, MD
Emory University
Winship Cancer Institute
Atlanta, Georgia

Peter Martin, MD
Weill Cornell Medical College
New York, New York

Ruben A. Mesa, MD
Mayo Clinic
Rochester, Minnesota

Craig Moskowitz, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

Nikhil Munshi, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Stephen Nimer, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

Susan O’Brien, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Owen A. O’Connor, MD, PhD
New York University
Langone Medical Center
New York, New York

Robert Z. Orlowski, MD, PhD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota
Gail J. Roboz, MD
Weill Cornell Medical College
New York, New York

Gary Schiller, MD, FACP
University of California Los Angeles
Los Angeles, California

Richard T. Silver, MD
Weill Cornell Medical College
New York, New York

Steven P. Treon, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts

Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering
Cancer Center

ENDORSED BY
New York-Presbyterian Weill Cornell Medical Center


Friday, April 30, 2010

8:00 am
Introduction & Pre-session audience survey
Hagop M. Kantarjian, MD – chairperson
John P. Leonard, MD – chairperson
Robert Z. Orlowski, MD, PhD – chairperson



Acute Leukemia Session

8:10 am
Debate: Is chemotherapy still useful for APL in the era of ATRA and arsenic trioxide?

ATRA + chemotherapy is still important
Harry P. Erba, MD, PhD

ATRA + non-chemotherapeutiic agents is better
Gary Schiller, MD

8:35 am
Debate: What is the most appropriate and effective therapy for elderly AML patients?

High Intensity therapy
Gary Schiller, MD

Low Intensity therapy
Harry Erba, MD, PhD

9:00 am
Emerging novel and promising therapeutic agents for AML
Stephen Nimer, MD

9:25 am
Coffee Break


Lymphoma Session I
9:45 am
Debate: Should the results of interim PET scans change the planned management of advanced Hodgkins Lymphoma or Diffuse Large B-cell Lymphoma?
Yes – Morton Coleman, MD
No – Craig Moskowitz, MD

10:10 am
Debate: Should surveillance CT scans be performed on DLBC Lymphoma patients who achieve a CR from frontline therapy?
Yes – Andrew D. Zelenetz, MD, PhD
No – Peter Martin, MD

10:35 am
Debate: What is the most appropriate second line therapy for advanced Follicular Lymphoma patients who relapse following frontline R-CHOP?
Autologous Stem Cell Transplant
Craig Moskowitz, MD

Radioimmunotherapy
Andrew D. Zelenetz, MD, PhD

Systemic chemotherapy
John P. Leonard, MD

11:05 am
What is the most appropriate management for stage I Follicular Lymphoma in a young patient – deciding when and with what to initiate therapy?
John P. Leonard, MD

11:35 am
Lunch

Myeloma Session I
12:40 pm
Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed Multiple Myeloma patients?
Yes – Sagar Lonial, MD
No – S. Vincent Rajkumar, MD

1:05 pm
Debate: What is the most appropriate frontline regimen for transplant ineligible Myeloma patients?
MPT – Steve P. Treon, MD, PhD
MPV – Sagar Lonial, MD
MPR – S. Vincent Rajkumar, MD

1:30 pm
The next great therapeutic challenge in Multiple Myeloma: Designing novel agents and combinations to overcome myeloma cell resistance to proteasome and immunomodulatory agents
Nikhil Munshi, MD

1:55 pm
Debate: For newly diagnosed SCT-eligible Myeloma patients the most appropriate induction therapy is:
A two drug regimen
Sagar Lonial, MD

A three drug regimen
Nikhil Munshi, MD

A four drug regimen
Shaji Kumar, MD

2:35 pm
Coffee Break


CML Session
2:55 pm
Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML?
Imatinib is still the standard of care
Eric Feldman, MD

New generation TKIs are the new standard of care
Hagop M. Kantarjian, MD

3:25 pm
Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML?
Allogeneic SCT
Stephen Nimer, MD

Second generation TKIs
Jorge Cortes, MD

3:55 pm
Evolving & Promising therapeutic strategies for post-TKI failure in CML
Hagop M. Kantarjian, MD

4:20 pm
Summary & Post-session audience survey

4:30 pm
Adjourn

Saturday, May 1, 2010

8:00 am
Introduction & Pre-session audience survey
Hagop M. Kantarjian, MD – chairperson
John P. Leonard, MD – chairperson
Robert Z. Orlowski, MD, PhD – chairperson


CLL Session
8:05 am
Moderator: James Epstein, MD
Debate: FCR is the best frontline therapy for CLL patient ≥65 years of age

Yes, FCR is the new standard of care
Susan O’Brien, MD

No, chlorambucil based therapy is the standard of care
Asher A. Chanan-Khan, MD

8:30 am
Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL?
No significant role
Susan O’Brien, MD

Major significant role
Asher A. Chanan-Khan, MD

Myeloproliferative Neoplasm Session
8:55 am
Moderator: Richard T. Silver, MD
How I deal with the difficult questions in the Management of Essential Thrombocythemia
Ruben A. Mesa, MD

9:25 am
What is the role of allogeneic transplantation in Myeloproliferative Neoplasms?
Allo-SCT should be used earlier and more often in MPNs
Ronald Hoffman, MD

Allo-SCT should be used only when systemic therapy is inappropriate or has failed
Ruben A. Mesa, MD



Myeloma Session II
9:50 am
How I manage Multiple Myeloma patients who present with significant pre-existing illnesses or serious complications of the Myeloma:
A 68 year old former professional wrestler with a long history of back and joint problems is diagnosed with IgG-kappa Myeloma and multiple vertebral compression fractures – S. Vincent Rajkumar, MD

10:05 am
Coffee Break

10:25 am
How I manage Multiple Myeloma patients who present with significant pre-existing illnesses or serious complications of the Myeloma:
A 51 year old man presents with light chain Myeloma and a serum creatinine of 5.5 mg/dl
Rafael Fonseca, MD

A 46 year old woman with juvenile diabetes presents with IgG-lambda Myeloma and evidence of significant peripheral neuropathy
Shaji Kumar, MD

10:50 am
Debate: For newly diagnosed Multiple Myeloma patients who relapse from a ≥VGPR response more than 12 months following frontline therapy, what is the best salvage strategy?
Re-treat with the previously effective frontline therapy
Robert Z. Orlowski, MD

Alternate immunomodulatory based regimens with proteasome inhibitor- based regimens
Rafael Fonseca, MD

11:15 am
Debate: How should bisphosphonates be utilized in Multiple Myeloma patients responding to frontline therapy?
2 years of bisphosphonates therapy is appropriate for most patients
Speaker Invited

Briefer courses are more appropriate for most patients
Robert Z. Orlowski, MD, PhD

11:40 am
Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia?
Yes – Shaji Kumar, MD
No – Steven P. Treon, MD, PhD

12:10 pm
Lunch



Lymphoma Session II
1:10 pm
Moderator: James Epstein, MD
Emerging and Promising Novel Agents for B-cell and T-cell Lymphomas
Owen A. O’Connor, MD, PhD

1:40 pm
Debate: Should treatment for limited stage non-bulky Hodgkins Lymphoma include radiation therapy?
Yes – Peter Martin, MD
No – Morton Coleman, MD

2:05 pm
Coffee Break



MDS Session
2:25 pm
Moderator: Richard T. Silver, MD
Debate: What is the best therapy for MDS patients with deletion 5q?
Lenalidomide is the best choice for all deletion 5q patients
Gail J. Roboz, MD

Lenalidomide is not the best choice for most deletion 5q patients
G. Garcia-Manero, MD

2:50 om
Debate: What is the best frontline therapy for intermediate-2 and high risk MDS?
Azacytidine is the standard of care
Gail J. Roboz, MD

The standard of care is not yet well defined
Eric Feldman, MD

3:15 pm
Novel & Evolving Therapeutic Strategies for MDS
Guillermo Garcia-Manero, MD

3:40 pm
Summary & Post-session audience survey

4:00 pm
Adjourn

Information coming soon.

Register Now

 

Registration Fees

Regular........................................$150.00
If payment received by April 22, 2010

Full/Onsite...................................$250.00
If payment received after April 22, 2010

Nurses/Residents/Students*.....$75.00
*proof of eligibility must accompany registration

 

Registration Procedures

To Register: You may register online by April 22, 2010 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than April 22, 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions:Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 22, 2010. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 22, 2010.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

 

The Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
www.westinny.com

The fragrant aroma of White Tea welcomes you upon arrival at The Westin New York at Times Square. Discover 863 rooms and suites with a soothing color palette and views of New York City and the Hudson River. Utilize such modern amenities as high-speed internet access with wireless connectivity available in select rooms. Note the personal touches, like the custom-designed terry bathrobe. Experience a rejuvenated transformation when you awake in Westin’s Heavenly Bed® or step from Westin’s Heavenly Bath®.

For the convenience of attendees, a limited number of rooms have been reserved until April 8, 2010 at a discounted rate of $229 single/double occupancy, plus tax, currently at 14.75%. This rate is not guaranteed outside the conference dates or after April 8, 2010.

To reserve your room please contact the Westin New York at Times Square reservations department at (212) 201 2700. To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in Hematologic Malignancies group. Reservation requests received after April 8, 2010 may not be guaranteed the group rate.

Dear Colleagues,

It is with great pleasure and enthusiasm that we invite you to attend Great Debates and Updates in Hematologic Malignancies, taking place April 30 – May 1, 2010 in New York, New York.Covering the broad continuum of hematologic malignancies, from lymphoma to leukemia to myeloma to myeloproliferative disorders, this one-of-a-kind hematology conference has a broad appeal to attendees and provides the most substantial curriculum. Using a combination of didactic presentations, as well as discussions in areas of controversy in hematology, the highly-informative “debate” format is one that you will find both
enjoyable and educational.

Attendees will have the chance to interact with nationally-recognized thought leaders who will take opposing positions on topics of interest and provide you with an insightful look at more than one side of a question.Discussions will focus on how the new data fits into the current community practice of hematology, and will be aimed at facilitating rapid incorporation of important new advances in treatment into your current practice.

For any healthcare professional interested and/or involved in the management and treatment of patients with hematologic malignancies, this conference is one that you will not want to miss! We look forward to seeing you in New York for what promises to be a rewarding professional update!

Sincerely,
Hagop Kantarjian, MD
John P. Leonard, MD
Robert Z. Orlowski, MD, PhD



ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

PDF Announcement

Exhibit Manual

The following companies have provided an educational grant in support of this conference:

GOLD

Genentech BioOncology and Biogen Idec

 

SILVER

Bristol-Myers Squibb

Cephalon

Millennium

BRONZE

Celegene

Novartis

 

 

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

 

The following companies are exhibitors at this conference:

Allos

American Express

Celegene

Cephalon

Genentech BioOncology and Biogen Idec

Merck

Millennium

Spectrum Pharmaceuticals

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.